# Pinealon Peptide

> Pinealon is the Glu-Asp-Arg tripeptide studied in cellular stress responses and age-related neuronal signaling.

Canonical: https://pepflow.app/peptides/pinealon/

The Tiny Bioregulator

Pinealon is the Glu-Asp-Arg (EDR) tripeptide studied in cell and animal models of neuronal stress and aging.

Brain health  Neuroaging biology

Tier E

Evidence Limited

Safety Limited Data

FDA status Not Approved

Last reviewed October 25, 2026 37 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is Pinealon?

Pinealon is Glu-Asp-Arg (EDR), a short tripeptide in the peptide-bioregulator literature. Cell and animal studies examine neuronal stress, aging, and signaling.[\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/22567179/>)

Its appeal comes from the small size and bioregulator tradition.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[16\]](<https://pubmed.ncbi.nlm.nih.gov/33396470/>)

Pinealon differs from Epithalon/Epitalon in its sequence and evidence base.[\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>)

## What Pinealon is investigated for

Pinealon evidence is grouped by practical use case and oral route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Cognitive clarity and brain aging support Oral 28% Limited

Cognition claims are indirect preclinical biology rather than nootropic certainty.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

#### Human evidence

Human memory or mental-clarity benefits have not been established for Pinealon.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/22708445/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/23734521/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/26390612/>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/28539017/>)

#### Animal / mechanistic evidence

Short-peptide aging literature and nuclear/DNA interaction work provide indirect plausibility for brain-aging claims.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

### ### Neuroprotection Oral 26% Limited

Neuroprotection remains an early mechanistic claim.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

#### Human evidence

Human neuroprotective benefits have not been established for Pinealon.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/22708445/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/23734521/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/26390612/>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/28539017/>)

#### Animal / mechanistic evidence

The neuroprotection rationale is inferred from short-peptide aging, cellular signaling, and DNA-interaction studies.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

### ### Melatonin and pineal regulation Oral 24% Limited

Melatonin and pineal-support claims remain preclinical and separate from proven sleep therapy.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

#### Human evidence

Human sleep or melatonin-regulation benefits have not been established for Pinealon.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/22708445/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/23734521/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/26390612/>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/28539017/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

#### Animal / mechanistic evidence

Organotypic pineal-cell culture and animal illumination-regimen work support a pineal-axis hypothesis.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

### ### Cellular aging and longevity support Oral 22% Limited

Longevity support remains an animal and mechanistic hypothesis.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

#### Human evidence

Human lifespan extension or disease prevention has not been established for Pinealon.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/22708445/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/26390612/>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/28539017/>)

#### Animal / mechanistic evidence

Animal and short-peptide aging publications support a geroprotective hypothesis under experimental conditions.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

## Evidence snapshot

### Overall confidence

Limited

30%

Pinealon remains a low-confidence bioregulator. Its potential cognitive and longevity benefits are not established in people.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/22708445/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/23734521/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/26390612/>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/28539017/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[17\]](<https://pubmed.ncbi.nlm.nih.gov/34071923/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

12%

### Human evidence

Insufficient

Human evidence is limited, with no reliable independent treatment benefit established.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/22708445/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/23734521/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/26390612/>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/28539017/>)

20%

### Animal / preclinical

Limited

Animal and mechanistic bioregulator literature supports neuroprotection plausibility, but translation remains uncertain.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18546825/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/18546826/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/21809624/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/22567179/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/25051764/>) [\[14\]](<https://pubmed.ncbi.nlm.nih.gov/28976148/>) [\[17\]](<https://pubmed.ncbi.nlm.nih.gov/34071923/>) [\[18\]](<https://pubmed.ncbi.nlm.nih.gov/39518916/>) [\[19\]](<https://pubmed.ncbi.nlm.nih.gov/41020860/>)

30%

### Mechanism support

Limited

Pinealon is discussed as a short peptide that may influence gene expression and neuronal stress responses. That mechanism is plausible but not enough to establish cognitive or longevity outcomes.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

## Forms & administration

Pinealon is tracked as an oral short-peptide product. Oral peptide identity, formulation, and market category vary, so protocol context stays product-specific.[\[22\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pinealon%22&limit=1>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>)

Oral

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Oral protocols use 1-2 mg per day. Injectable protocols use about 1 mg per dose.[\[22\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pinealon%22&limit=1>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>)

### Frequency

Oral and injectable protocols are once daily.[\[22\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pinealon%22&limit=1>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>)

### Timing Considerations

Morning is the usual timing.[\[22\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pinealon%22&limit=1>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>)

### Cycle Length

Oral cycles run 4-8 weeks. Injectable cycles run about 20 days.[\[22\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pinealon%22&limit=1>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>)

[Full Pinealon dosage guide](<https://pepflow.app/peptides/pinealon/dosage/>)

## What to expect

### First week

Oral Pinealon use may feel like changes in sleep-wake rhythm, morning energy, concentration, or mental fatigue.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>) [\[22\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pinealon%22&limit=1>)

### Weeks 4-8

Oral cognition-oriented effects may appear as steadier memory routines, daily energy, mood, or sleep regularity.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>) [\[22\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pinealon%22&limit=1>)

### After stopping

Perceived cognition, energy, or sleep-rhythm changes may drift back toward baseline after oral Pinealon use ends.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>) [\[22\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pinealon%22&limit=1>)

## Safety profile

Pinealon safety is an oral neuroactive-peptide question, with sleep, mood, product quality, pregnancy, and repeated cycles driving caution.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

### Cautions

- Sparse human data[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)
- Neuroactive context[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)
- Product quality[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

### What we don't know

Pharmacokinetics, interactions, reproductive safety, and long-term repeated-cycle effects remain unclear.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

## Who Pinealon is not for

Route-specific avoid and medical-review notes:

- **Pregnancy or breastfeeding**

  Pregnancy or breastfeeding warrants medical review or avoidance for Pinealon.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)
- **Unstable neurologic or psychiatric symptoms**

  Unstable neurologic or psychiatric symptoms warrants medical review or avoidance for Pinealon.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **Sleep aids / sedatives**

  Melatonin, antihistamine sleep aids, benzodiazepines, or alcohol can compound grogginess or dream changes; this is a theoretical neuroactive caution.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)
- **Stimulants / nootropics**

  Stimulants, high-caffeine products, or nootropic stacks can counter sleep effects and confound cognitive tracking; this is a theoretical neuroactive caution.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)
- **Psychiatric medications**

  Antidepressants, antipsychotics, or mood stabilizers can make mood, sleep, or cognition changes harder to attribute; this is a theoretical neuroactive caution.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

## Regulatory status

### United States

In the U.S. as of 2026-06-21, Pinealon has no FDA-approved drug product for the reviewed oral route. Research-market supply and compounded preparations are separate from approval; the 503A row names the current compounding bucket.[\[22\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pinealon%22&limit=1>) [\[23\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[26\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[27\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Oral | Not Approved · Pinealon is not FDA-approved as an oral drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[\[22\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pinealon%22&limit=1>) [\[23\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[26\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[27\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) | Not Listed · Pinealon is not in the current reviewed 503A compounding bucket for the oral route; compounding status is separate from FDA drug approval.[\[22\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pinealon%22&limit=1>) [\[23\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[26\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[27\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) |

### Oral

FDA drug approval

Not Approved

Pinealon is not FDA-approved as an oral drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[\[22\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pinealon%22&limit=1>) [\[23\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[26\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[27\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

503A compounding

Not Listed

Pinealon is not in the current reviewed 503A compounding bucket for the oral route; compounding status is separate from FDA drug approval.[\[22\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pinealon%22&limit=1>) [\[23\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[26\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[27\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

### International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets.[\[29\]](<https://www.ema.europa.eu/en/medicines>) [\[30\]](<https://products.mhra.gov.uk/>) [\[31\]](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>) [\[32\]](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)

### Sports & competition

WADA S0 can apply to non-approved pharmacological substances that are not otherwise named. Tested athletes should not treat Pinealon oral route as athlete-cleared without sport-specific review.[\[24\]](<https://ita.sport/resource/wada-2026-prohibited-list/>) [\[22\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pinealon%22&limit=1>) [\[23\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[26\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[27\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

## How it works

Pinealon is a short Glu-Asp-Arg peptide discussed around gene expression, nuclear access, DNA interaction, and neuronal or pineal-cell stress responses. The practical question is whether a very small peptide can shift cell activity enough to matter for aging or cognition.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

Oral delivery is the weak link for interpretation. A peptide has to survive product handling and digestion, reach relevant tissue, and produce meaningful exposure before cell-culture or animal mechanisms can support a human longevity or cognitive-performance claim. The mechanism remains background biology, not a protocol-level claim.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

## Research gaps & open questions

What the current literature has not yet settled about Pinealon:

01

Modern randomized trials need to show whether Pinealon meaningfully improves memory, attention, sleep, or day-to-day cognitive function in people.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

02

Different oral tablets, capsules, and peptide formulations need studies showing how much Pinealon is absorbed and how long it lasts.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

03

Long-term studies need to determine whether repeated Pinealon cycles remain safe and whether benefits or harms accumulate.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

## Common questions

### Is Pinealon FDA-approved?

No. Pinealon is not FDA-approved in the U.S. for oral drug use, and supplement or research-market availability is not FDA approval.[\[22\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pinealon%22&limit=1>) [\[23\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>)

### Is Pinealon the same as Epithalon?

No. Pinealon is Glu-Asp-Arg (EDR), while Epithalon/Epitalon is associated with Ala-Glu-Asp-Gly (AEDG). Their identities and evidence should not be merged.[\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>)

### Does Pinealon improve memory?

Not proven. A reliable improvement in human memory has not been established.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/22708445/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/23734521/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/26390612/>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/28539017/>)

## Myths & misconceptions

### Myth

A three-amino-acid peptide is automatically safe.

### Reality

Small size does not replace product-quality, route, and human safety evidence.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

### Myth

Bioregulator status proves anti-aging benefit.

### Reality

Bioregulator framing is a hypothesis and tradition, not a clinical endpoint.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

## History & discovery

Pinealon sits in the short-peptide bioregulator tradition, where small tissue-associated peptides were studied for aging, gene-expression, and neuroendocrine effects. Its public story comes from that gerontology literature. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

Reviews and animal work placed Pinealon near peptide-aging and illumination-regimen studies. That origin explains longevity-market interest, but it does not establish oral human cognitive benefit.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

Fluorescent-peptide and pineal-cell culture studies shifted attention toward nuclear entry, DNA interaction, and signaling molecules. Those findings shaped mechanism claims while leaving route and outcome questions open.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)

## Published research 37 citations

Pinealon research focuses on neuronal stress, cognition and age-related signaling. Clinical evidence remains limited, with no established independent cognitive or longevity benefit.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18546825/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/18546826/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/21809624/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/21978084/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/22567179/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/22708445/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/23581987/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/23734521/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/24738258/>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/24909721/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/25051764/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/26390612/>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/28539017/>) [\[14\]](<https://pubmed.ncbi.nlm.nih.gov/28976148/>) [\[15\]](<https://pubmed.ncbi.nlm.nih.gov/30762356/>) [\[16\]](<https://pubmed.ncbi.nlm.nih.gov/33396470/>) [\[17\]](<https://pubmed.ncbi.nlm.nih.gov/34071923/>) [\[18\]](<https://pubmed.ncbi.nlm.nih.gov/39518916/>) [\[19\]](<https://pubmed.ncbi.nlm.nih.gov/41020860/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/22117547/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/22803060/>) [\[22\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pinealon%22&limit=1>) [\[23\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[24\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

- [\[1\] **\[Investigation of antihypoxic properties of short peptides\]** Adv Gerontol, 2008. animal.](<https://pubmed.ncbi.nlm.nih.gov/18546825/>)
- [\[2\] **\[Biological activity of regulatory peptides in model experiments in vitro\]** Adv Gerontol, 2008. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/18546826/>)
- [\[3\] **\[Effects of introduction of short peptides before carotid artery occlusion on behaviour and caspase-3 activity in the brain of old rats\].** Advances in Gerontology, 2011. animal.](<https://pubmed.ncbi.nlm.nih.gov/21809624/>)
- [\[4\] **Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes.** Rejuvenation Research, 2011 Oct. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/21978084/>)
- [\[5\] **Pinealon protects the rat offspring from prenatal hyperhomocysteinemia.** International Journal of Clinical and Experimental Medicine, 2012. animal.](<https://pubmed.ncbi.nlm.nih.gov/22567179/>)
- [\[6\] **\[Analysis of some parameters of biological age and adaptation possibilities of workers of locomotive brigades\].** Advances in Gerontology, 2012. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/22708445/>)
- [\[7\] **Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides.** Biochemistry (Mosc), 2013 Feb. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/23581987/>)
- [\[8\] **\[The peptide correction of neurotic disorders among professional truck-drivers\].** Advances in Gerontology, 2012. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/23734521/>)
- [\[9\] **\[Neuroprotective effects of peptides bioregulators in people of various age\].** Advances in Gerontology, 2013. review.](<https://pubmed.ncbi.nlm.nih.gov/24738258/>)
- [\[10\] **Short peptides stimulate serotonin expression in cells of brain cortex.** Bull Exp Biol Med, 2014 May. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/24909721/>)
- [\[11\] **\[Regulation of content of cytokines in blood serum and of caspase-3 activity in brains of old rats in model of sharp hypoxic hypoxia with Cortexin and Pinealon\].** Advances in Gerontology, 2014. animal.](<https://pubmed.ncbi.nlm.nih.gov/25051764/>)
- [\[12\] **\[EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION\]** Adv Gerontol, 2015. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/26390612/>)
- [\[13\] **\[Comparative analysis of different methods of geroprotective\].** Advances in Gerontology, 2016. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/28539017/>)
- [\[14\] **\[Effect of peptide geroprotectors on the navigation system learning and caspase-3 in brain structures in rats of different age\].** Advances in Gerontology, 2013. animal.](<https://pubmed.ncbi.nlm.nih.gov/28976148/>)
- [\[15\] **Role of Mono- and Divalent Ions in Peptide Glu-Asp-Arg-DNA Interaction.** The Journal of Physical Chemistry B, 2019 Mar 7. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/30762356/>)
- [\[16\] **EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer’s Disease.** Molecules, 2020 Dec 31. review.](<https://pubmed.ncbi.nlm.nih.gov/33396470/>)
- [\[17\] **Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's Disease.** Pharmaceuticals (Basel), 2021 May. animal.](<https://pubmed.ncbi.nlm.nih.gov/34071923/>)
- [\[18\] **Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes.** Int J Mol Sci, 2024 Oct 22. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/39518916/>)
- [\[19\] **The Influence of Short Peptides on Cell Senescence and Neuronal Differentiation** Current Issues in Molecular Biology, 2025-09-10. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/41020860/>)
- [\[20\] **Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.** Biochemistry (Mosc), 2011 Nov. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/22117547/>)
- [\[21\] **Effect of short peptides on expression of signaling molecules in organotypic pineal cell culture.** Bull Exp Biol Med, 2011 Nov. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)
- [\[22\] **Drugs@FDA/openFDA query for Pinealon** U.S. Food and Drug Administration. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22Pinealon%22&limit=1>)
- [\[23\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[24\] **The 2026 List of Prohibited Substances and Methods** World Anti-Doping Agency. regulatory.](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- [\[25\] **FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)
- [\[26\] **Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act** U.S. Food and Drug Administration, 2026-05-14. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)
- [\[27\] **Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act** U.S. Food and Drug Administration, 2025-01-07. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)
- [\[28\] **Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks** U.S. Food and Drug Administration, 2026-04-22. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- [\[29\] **European Medicines Agency medicines search** European Medicines Agency. official guidance.](<https://www.ema.europa.eu/en/medicines>)
- [\[30\] **MHRA Products search** Medicines and Healthcare products Regulatory Agency. official guidance.](<https://products.mhra.gov.uk/>)
- [\[31\] **Drug Product Database: Access the database** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>)
- [\[32\] **Searching the Australian Register of Therapeutic Goods** Therapeutic Goods Administration. official guidance.](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)
- [\[33\] **Cosmetic Products Regulation** European Commission. official guidance.](<https://single-market-economy.ec.europa.eu/sectors/cosmetics/legislation_en>)
- [\[34\] **Making cosmetic products available to consumers in Great Britain** UK Office for Product Safety and Standards. official guidance.](<https://www.gov.uk/guidance/making-cosmetic-products-available-to-consumers-in-great-britain>)
- [\[35\] **Cosmetics regulatory information** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/consumer-product-safety/cosmetics/regulatory-information.html>)
- [\[36\] **Cosmetics and soap** Australian Industrial Chemicals Introduction Scheme. official guidance.](<https://www.industrialchemicals.gov.au/cosmetics-and-soap>)
- [\[37\] **Tetrapeptide H-Glu-Asp-Arg-Arg-OH stimulates expression of cytoskeletal and nuclear matrix proteins.** Bull Exp Biol Med, 2012 Aug. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/22977870/>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

Bioregulator peptide

**Tier**

E

**Evidence**

30% Limited

**Safety**

Limited Data

**FDA status**

Not Approved

**Oral 503A**

Not Listed

**Citations**

[37 citations](<https://pepflow.app/peptides/pinealon/#published-research>)

**Updated**

October 25, 2026

### Potential benefits

- Cognitive clarity and brain aging support
- Neuroprotection
- Melatonin and pineal regulation
- Cellular aging and longevity support

### Also known as

- Glu-Asp-Arg
- EDR
- Glu-Asp-Arg tripeptide

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [Pinealon dosage guide](<https://pepflow.app/peptides/pinealon/dosage/>)
- [PepFlow Library Statistics (2026) · 65 Profiles](<https://pepflow.app/research/peptide-library/>)
